DBV Technologies | DBVT - Betriebsaufwand

Aktienkurs
19.79
Täglich Wechseln
-0.20 -1.00%
Monatlich
-7.52%
Jährlich
101.32%
Q2 Prognose
19.41




Betriebsaufwand Veränderung Datum
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
DBV Technologies USD 37.05M 4.06M 2025-09
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Galectin Therapeutics USD 11.29M 1.64M 2024-06
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Insmed USD 506.24M 7.31M 2026-03
Ionis Pharmaceuticals USD 364M 54M 2026-03
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03